Medpace/$MEDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Employees
6,300
Headquarters
Website
Medpace Metrics
BasicAdvanced
$13bn
28.57
$15.90
1.19
-
Price and volume
Market cap
$13bn
Beta
1.19
52-week high
$628.92
52-week low
$294.07
Average daily volume
366k
Financial strength
Current ratio
0.847
Quick ratio
0.779
Long term debt to equity
20.433
Total debt to equity
24.418
Profitability
EBITDA (TTM)
591.015
Gross margin (TTM)
71.90%
Net profit margin (TTM)
17.19%
Operating margin (TTM)
21.02%
Effective tax rate (TTM)
19.48%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
17.47%
Return on equity (TTM)
77.25%
Valuation
Price to earnings (TTM)
28.567
Price to revenue (TTM)
4.81
Price to book
21.68
Price to tangible book (TTM)
-133.27
Price to free cash flow (TTM)
18.119
Free cash flow yield (TTM)
5.52%
Free cash flow per share (TTM)
25.07
Growth
Revenue change (TTM)
24.19%
Earnings per share change (TTM)
21.48%
3-year revenue growth (CAGR)
19.66%
10-year revenue growth (CAGR)
23.22%
3-year earnings per share growth (CAGR)
26.43%
10-year earnings per share growth (CAGR)
58.13%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
MEDP Deadline: Rosen Law Firm Urges Medpace Holdings, Inc. (NASDAQ: MEDP) Stockholders to Contact the Firm for Information About Their Rights
Business Wire·17 hours ago
MEDP FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP
Newsfile Corp·17 hours ago
MEDP INVESTOR ACTION: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
Newsfile Corp·20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs